PWPS
CTKB icon

Pinnacle Wealth Planning Services’s Cytek Biosciences CTKB Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.8K Buy
4,313
+825
+24% +$3.9K ﹤0.01% 1718
2025
Q4 		$17.6K Buy
+3,488
New +$16.2K ﹤0.01% 1778

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pinnacle Wealth Planning Services's CTKB Position: Q1 2026 in Review

Pinnacle Wealth Planning Services increased its Cytek Biosciences (CTKB) stake by 24% in Q1 2026, buying an estimated $3.9K and bringing the position to 4,313 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1718.

Pinnacle Wealth Planning Services first reported a position in CTKB in Q4 2025 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Pinnacle Wealth Planning Services held 4,313 shares of Cytek Biosciences worth $18.8K as of Q1 2026.
  • Pinnacle Wealth Planning Services bought 825 Cytek Biosciences shares in Q1 2026, an estimated $3.9K.
  • Cytek Biosciences made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #1718 holding.
  • Pinnacle Wealth Planning Services first reported a position in Cytek Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.